MSH2 (G219-1129) Mouse Monoclonal Antibody

MSH2
Anti-MSH2 positively labels well differentiated colon adenocarcinoma in a nuclear pattern.

MSH2 (G219-1129) Mouse Monoclonal Antibody

Specialties: Gastrointestinal (GI) Pathology

Updated: 2018-01-11 11:26:43

MSH2 is a mismatch repair protein which is deficient in a high proportion of patients with microsatellite instability (MSI-H). It has been suggested that the deficiencies in DNA mismatch repair protein(s) can be seen in some malignancies such as hereditary nonpolyposis colorectal cancer (HNPCC) and endometrial cancer. Anti-MSH2 may be useful in the identification of the the MSH2 protein in a variety of normal and neoplastic tissues and the identification of loss of MSH2 in tumors with MSI genotype.1-8 Anti-MSH2 is best utilized in an IHC panel that includes anti-MLH1, anti-MSH6, and anti-PMS2.

  1. Wright CL, et al. Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol. 2003; 27:1393-406. 
  2. Brueckl WM, et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res. 2003; 23:1773-8. 
  3. Rigau V, et al. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining. Arch Pathol Lab Med. 2003; 127: 694-700. 
  4. Renkonen E, et al. Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2003; 21:3629-37. 
  5. Hoedema R, et al. Genetic testing for hereditary nonpolyposis colorectal cancer. Am Surg. 2003; 5:387-91. 
  6. Christensen M, et al. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. Cancer. 2002; 95 2422-30. 
  7. Wahlberg SS, et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res. 2002; 62:3485-92.
  8. Lanza G, et al. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol. 2002; 15:741-9.

Specifications


  • Reactivity: paraffin
  • Control: Colon carcinoma (Nuclear); Colon mucosa (Nuclear)
  • Dilution Range: 1:100-1:500*

Package Inserts


IFU SDS

Ordering Information

For in vitro diagnostic (IVD) use in USA

25.0 mL predilute ready-to-use286M-10
0.1 mL concentrate286M-14
0.5 mL concentrate286M-15
1.0 mL concentrate286M-16
1.0 mL predilute ready-to-use286M-17
7.0 mL predilute ready-to-use286M-18

For in vitro diagnostic (IVD) use in Canada

25.0 mL predilute ready-to-use286M-10
0.1 mL concentrate286M-14
0.5 mL concentrate286M-15
1.0 mL concentrate286M-16
1.0 mL predilute ready-to-use286M-17
7.0 mL predilute ready-to-use286M-18

For in vitro diagnostic (IVD) use in Europe

25.0 mL predilute ready-to-use286M-10
0.1 mL concentrate286M-14
0.5 mL concentrate286M-15
1.0 mL concentrate286M-16
1.0 mL predilute ready-to-use286M-17
7.0 mL predilute ready-to-use286M-18

For research use only (RUO) in Japan

25.0 mL predilute ready-to-use (RUO)286M-10-RUO
0.1 mL concentrate (RUO)286M-14-RUO
0.5 mL concentrate (RUO)286M-15-RUO
1.0 mL concentrate (RUO)286M-16-RUO
1.0 mL predilute ready-to-use (RUO)286M-17-RUO
7.0 mL predilute ready-to-use (RUO)286M-18-RUO

 

To request information on this product in additional countries, please click the button below.

Request More Information